John Fanikos
Overview
Explore the profile of John Fanikos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
1700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scimeca G, Krishnathasan D, Rashedi S, Lan Z, Sato A, Hamade N, et al.
J Thromb Thrombolysis
. 2025 Mar;
PMID: 40064840
COVID-19 is associated with an increased risk of venous thromboembolism (VTE) in hospitalized patients. Although prior studies have attempted to identify predictors of VTE, restricted sample size and use of...
2.
Fera T, Burnett A, Grandoni J, Moore M, Nussbaum B, Pollack Jr C, et al.
J Pharm Pract
. 2024 Jul;
38(1):7-12.
PMID: 39030931
Medication-use evaluations are meant to ensure that medication-use processes are consistent with prevailing standards of care, assure optimal use of therapy, and reduce the risk of medication-related problems. Reversal agents...
3.
Alhammad A, Stashek C, Churchill W, Fanikos J
Hosp Pharm
. 2024 May;
51(1):49-53.
PMID: 38745723
Background: Interruptions in the pharmacy setting by nurses are common. While the source of nurse-generated interruptions may be variable, the appropriateness of these interruptions remains unknown. Objective: To evaluate the...
4.
Low absolute risk of thrombotic and cardiovascular events in outpatient pregnant women with COVID-19
Bikdeli B, Krishnathasan D, Khairani C, Bejjani A, Davies J, Porio N, et al.
Thromb Res
. 2024 Apr;
237:209-215.
PMID: 38677791
Introduction: Pregnancy may contribute to an excess risk of thrombotic or cardiovascular events. COVID-19 increases the risk of these events, although the risk is relatively limited among outpatients. We sought...
5.
Alkhezi O, Buckley L, Fanikos J
Am J Cardiovasc Drugs
. 2024 Apr;
24(3):433-444.
PMID: 38583107
Background: Landmark clinical trials have expended the indications for the direct oral anticoagulants (DOACs), but contemporary data on usage and expenditure patterns are lacking. Objective: This study aimed to assess...
6.
Al Zaria M, Buckley L, Dellorfano H, Manzo P, Fanikos J
J Thromb Thrombolysis
. 2024 Mar;
57(4):598-602.
PMID: 38554223
Moderate-strong CYP3A4 or Pgp inhibitors and inducers alter direct oral anticoagulant (DOAC) pharmacokinetics. Whether the presence of a DOAC drug-drug interaction (DDI) prompts in- hospital changes in management remains unknown....
7.
Talasaz A, Sadeghipour P, Ortega-Paz L, Kakavand H, Aghakouchakzadeh M, Beavers C, et al.
Nat Rev Cardiol
. 2024 Mar;
21(8):574-592.
PMID: 38509244
Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an...
8.
Goodman S, Roy D, Pollack Jr C, Leblanc K, Kwaku K, Barnes G, et al.
Crit Pathw Cardiol
. 2024 Feb;
23(2):47-57.
PMID: 38381695
The global prevalence of atrial fibrillation is rapidly increasing, in large part due to the aging of the population. Atrial fibrillation is known to increase the risk of thromboembolic stroke...
9.
Bejjani A, Khairani C, Assi A, Piazza G, Sadeghipour P, Talasaz A, et al.
J Am Coll Cardiol
. 2024 Jan;
83(3):444-465.
PMID: 38233019
For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism treatment. However, randomized controlled trials suggest that...
10.
Nuckols T, Berdahl C, Henreid A, Schnipper J, Rauf A, Ko E, et al.
Inquiry
. 2023 Dec;
60:469580231218625.
PMID: 38146178
Optimal medication management is important during hospitalization and at discharge because post-discharge adverse drug events (ADEs) are common, often preventable, and contribute to patient harms, healthcare utilization, and costs. Conduct...